Scholarlink

<p>Clinical implementation of neurofilament light chain (NfL), a biomarker of neurodegeneration, remains challenging due to absence of reliable cutoffs and influence of confounding factors, particularly age. We aimed to develop an age-adjusted, two-threshold classification framework to support clinical interpretation of NfL in the neurodegenerative dementia diagnosis. We retrospectively enrolled subjects with cognitive/behavioral disturbances and cognitively unimpaired controls (CTR). Participants underwent a baseline diagnostic workup, including at least a neuropsychological assessment, blood test, CSF and serum NfL measurement, and MRI, and were followed up for 2&#xa0;years. At follow-up, they were diagnosed with either a neurodegenerative dementia [Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), or Lewy Body Dementia (LBD)] or a non-neurodegenerative condition [Other Etiology (OE)]. AD, FTD, and LBD were grouped as Neurodegenerative (NDG), while OE and CTR were grouped as Non-Neurodegenerative (non-NDG). Bayesian regression models assessed the effects of age, disease duration, renal function, and gender on NfL. A weighted support vector machine (SVM) with leave-one-out cross-validation defined age-adjusted cutoffs using a two-threshold strategy constraining sensitivity ≥ 85% and limiting the intermediate zone. We included 217 subjects (158 NDG, 59 non-NDG). Serum and CSF NfL levels were significantly higher in NDG. Age strongly increased NfL levels, particularly in serum where diagnostic separation declined beyond age 70. The SVM-based model applied to CSF NfL defined continuous, age-adjusted, two-threshold cutoffs, identifying low-risk, high-risk, and intermediate zones. The proposed framework for CSF NfL provides a clinically oriented decision-support tool to stratify the likelihood of underlying neurodegeneration and guide diagnostic workup in cognitive neurology settings, pending external validation.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-adjusted neurofilament light chain cutoffs for diagnosing neurodegenerative dementia: a two-threshold machine learning approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Chiara Gallingani,
  • Riccardo Maramotti,
  • Chiara Carbone,
  • Giulia Vinceti,
  • Silvia Cossutti,
  • Najara Iacovino,
  • Daniela Ballotta,
  • Simone Salemme,
  • Teresa Urbano,
  • Roberta Bedin,
  • Annalisa Chiari,
  • Giovanna Zamboni,
  • Manuela Tondelli

摘要

Clinical implementation of neurofilament light chain (NfL), a biomarker of neurodegeneration, remains challenging due to absence of reliable cutoffs and influence of confounding factors, particularly age. We aimed to develop an age-adjusted, two-threshold classification framework to support clinical interpretation of NfL in the neurodegenerative dementia diagnosis. We retrospectively enrolled subjects with cognitive/behavioral disturbances and cognitively unimpaired controls (CTR). Participants underwent a baseline diagnostic workup, including at least a neuropsychological assessment, blood test, CSF and serum NfL measurement, and MRI, and were followed up for 2 years. At follow-up, they were diagnosed with either a neurodegenerative dementia [Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), or Lewy Body Dementia (LBD)] or a non-neurodegenerative condition [Other Etiology (OE)]. AD, FTD, and LBD were grouped as Neurodegenerative (NDG), while OE and CTR were grouped as Non-Neurodegenerative (non-NDG). Bayesian regression models assessed the effects of age, disease duration, renal function, and gender on NfL. A weighted support vector machine (SVM) with leave-one-out cross-validation defined age-adjusted cutoffs using a two-threshold strategy constraining sensitivity ≥ 85% and limiting the intermediate zone. We included 217 subjects (158 NDG, 59 non-NDG). Serum and CSF NfL levels were significantly higher in NDG. Age strongly increased NfL levels, particularly in serum where diagnostic separation declined beyond age 70. The SVM-based model applied to CSF NfL defined continuous, age-adjusted, two-threshold cutoffs, identifying low-risk, high-risk, and intermediate zones. The proposed framework for CSF NfL provides a clinically oriented decision-support tool to stratify the likelihood of underlying neurodegeneration and guide diagnostic workup in cognitive neurology settings, pending external validation.

Graphical abstract